The sarcopenia treatment market size has grown strongly in recent years. It will grow from $3.3 billion in 2023 to $3.52 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The growth observed during the historical period can be attributed to several factors, including the aging population, increased awareness and diagnosis of medical conditions, lifestyle changes leading to health concerns, public health initiatives aimed at prevention and treatment, and regulatory approvals facilitating the availability of healthcare products and services.
The sarcopenia treatment market size is expected to see strong growth in the next few years. It will grow to $4.44 billion in 2028 at a compound annual growth rate (CAGR) of 6%. The anticipated growth in the forecast period is driven by various factors, including the adoption of personalized medicine, advancements in nutritional interventions, the integration of digital health platforms, initiatives focused on patient education and empowerment, and global health efforts. Major trends expected during this period include the rise of personalized therapies, the emergence of novel drug classes, the integration of digital health solutions, collaborative research initiatives, and continued investment in research and development.
The anticipated increase in malnutrition is poised to drive the growth of the sarcopenia treatment market in the future. Malnutrition encompasses deficiencies, excesses, or imbalances in an individual's intake of energy and nutrients, including both undernutrition and overweight, obesity, and diet-related noncommunicable diseases. Sarcopenia treatment plays a crucial role in addressing the concurrent conditions of malnutrition and sarcopenia in older adults through interventions such as nutritional therapy and exercise, with the aim of enhancing muscle mass, strength, and overall nutritional status. For instance, a report published by the World Health Organization (WHO) in December 2023 highlighted malnutrition as a significant global health challenge, with an estimated 462 million underweight individuals and 149 million children under 5 experiencing stunting in 2022. Consequently, the surge in malnutrition acts as a driving force behind the growth of the sarcopenia treatment market.
Major companies in the sarcopenia treatment market are intensifying their focus on developing multiple advanced clinical studies to enhance treatment options. A clinical study involves a systematic investigation conducted on human subjects to assess the safety, efficacy, and/or outcomes of a medical intervention. For instance, in September 2023, Biophytis, a France-based biotechnology company, disclosed the authorization from the Food and Drug Administration (FDA) to commence the SARA-31 Phase 3 study in sarcopenia. This study aims to assess the efficacy and safety of Sarconeos (BIO101) in treating sarcopenic patients at risk of motor disability. Representing a significant advancement in technological and pharmaceutical treatment modalities, this study offers potential benefits in terms of efficacy and safety for severe sarcopenic patients. Notably, it marks the first-ever Phase 3 study in sarcopenia to receive FDA authorization. The study will involve approximately 900 patients aged over 65 with sarcopenia, low walking speed, and low hand grip strength. The primary endpoints will include the evaluation of the risk of major mobility disability (MMD), walking speed, hand grip strength, and patient-reported quality of life.
In October 2021, Rejuveron Life Sciences AG, a biotechnology company headquartered in Switzerland, completed the acquisition of Rejuvenate Biomed NV for $16.99 million. This strategic move aims to expedite the clinical advancement of Rejuvenate's primary candidate, RJx-01, targeting both acute and chronic sarcopenia. Rejuvenate Biomed NV, based in Belgium, is a clinical-stage company committed to the exploration and creation of therapies aimed at postponing the onset of age-related illnesses, including sarcopenia.
Major companies operating in the sarcopenia treatment market report are Pfizer Inc., F-Hoffmann La-Roche, Merck Sharp & Dohme Corp. (Merck & Co.), AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories Inc., GlaxoSmithKline plc, Eli Lilly and Company, BASF SE, Nestle Health Science, Haleon Group of Companies, Regeneron Pharmaceuticals Inc., DSM, American Way (Amway) Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Ion Labs Inc., Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt. Ltd., Nutrafill.
North America was the largest region in the sarcopenia treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sarcopenia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sarcopenia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Sarcopenia treatment encompasses medical interventions and lifestyle strategies tailored to counteract age-related muscle loss, aiming to preserve or enhance skeletal muscle mass and function. The goal of treatment is to mitigate age-related muscle decline, bolster muscle strength, and improve overall physical function and mobility.
The main types of sarcopenia treatments include protein supplements, vitamin B12 supplements, vitamin D and calcium supplements, and others. Protein supplements, available in forms such as bars, powders, or shakes derived from whey, plant, or meat sources, are utilized for both primary and secondary sarcopenia treatment and can be administered orally, parenterally, or enterally. These supplements are distributed through various channels including hospital pharmacies, retail pharmacies, and online pharmacies.
The sarcopenia treatment market research report is one of a series of new reports that provides sarcopenia treatment market statistics, including sarcopenia treatment industry global market size, regional shares, competitors with a sarcopenia treatment market share, detailed sarcopenia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the sarcopenia treatment industry. This sarcopenia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The sarcopenia treatment market consists of revenues earned by entities by providing nutritional therapy, combination therapy, and muscle strength. The market value includes the value of related goods sold by the service provider or included within the service offering. The sarcopenia market also includes sales of muscle stimulators, orthopedic braces and supports, joint replacement implants, anabolic agents, and more. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The sarcopenia treatment market size is expected to see strong growth in the next few years. It will grow to $4.44 billion in 2028 at a compound annual growth rate (CAGR) of 6%. The anticipated growth in the forecast period is driven by various factors, including the adoption of personalized medicine, advancements in nutritional interventions, the integration of digital health platforms, initiatives focused on patient education and empowerment, and global health efforts. Major trends expected during this period include the rise of personalized therapies, the emergence of novel drug classes, the integration of digital health solutions, collaborative research initiatives, and continued investment in research and development.
The anticipated increase in malnutrition is poised to drive the growth of the sarcopenia treatment market in the future. Malnutrition encompasses deficiencies, excesses, or imbalances in an individual's intake of energy and nutrients, including both undernutrition and overweight, obesity, and diet-related noncommunicable diseases. Sarcopenia treatment plays a crucial role in addressing the concurrent conditions of malnutrition and sarcopenia in older adults through interventions such as nutritional therapy and exercise, with the aim of enhancing muscle mass, strength, and overall nutritional status. For instance, a report published by the World Health Organization (WHO) in December 2023 highlighted malnutrition as a significant global health challenge, with an estimated 462 million underweight individuals and 149 million children under 5 experiencing stunting in 2022. Consequently, the surge in malnutrition acts as a driving force behind the growth of the sarcopenia treatment market.
Major companies in the sarcopenia treatment market are intensifying their focus on developing multiple advanced clinical studies to enhance treatment options. A clinical study involves a systematic investigation conducted on human subjects to assess the safety, efficacy, and/or outcomes of a medical intervention. For instance, in September 2023, Biophytis, a France-based biotechnology company, disclosed the authorization from the Food and Drug Administration (FDA) to commence the SARA-31 Phase 3 study in sarcopenia. This study aims to assess the efficacy and safety of Sarconeos (BIO101) in treating sarcopenic patients at risk of motor disability. Representing a significant advancement in technological and pharmaceutical treatment modalities, this study offers potential benefits in terms of efficacy and safety for severe sarcopenic patients. Notably, it marks the first-ever Phase 3 study in sarcopenia to receive FDA authorization. The study will involve approximately 900 patients aged over 65 with sarcopenia, low walking speed, and low hand grip strength. The primary endpoints will include the evaluation of the risk of major mobility disability (MMD), walking speed, hand grip strength, and patient-reported quality of life.
In October 2021, Rejuveron Life Sciences AG, a biotechnology company headquartered in Switzerland, completed the acquisition of Rejuvenate Biomed NV for $16.99 million. This strategic move aims to expedite the clinical advancement of Rejuvenate's primary candidate, RJx-01, targeting both acute and chronic sarcopenia. Rejuvenate Biomed NV, based in Belgium, is a clinical-stage company committed to the exploration and creation of therapies aimed at postponing the onset of age-related illnesses, including sarcopenia.
Major companies operating in the sarcopenia treatment market report are Pfizer Inc., F-Hoffmann La-Roche, Merck Sharp & Dohme Corp. (Merck & Co.), AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories Inc., GlaxoSmithKline plc, Eli Lilly and Company, BASF SE, Nestle Health Science, Haleon Group of Companies, Regeneron Pharmaceuticals Inc., DSM, American Way (Amway) Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Ion Labs Inc., Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt. Ltd., Nutrafill.
North America was the largest region in the sarcopenia treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sarcopenia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sarcopenia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Sarcopenia treatment encompasses medical interventions and lifestyle strategies tailored to counteract age-related muscle loss, aiming to preserve or enhance skeletal muscle mass and function. The goal of treatment is to mitigate age-related muscle decline, bolster muscle strength, and improve overall physical function and mobility.
The main types of sarcopenia treatments include protein supplements, vitamin B12 supplements, vitamin D and calcium supplements, and others. Protein supplements, available in forms such as bars, powders, or shakes derived from whey, plant, or meat sources, are utilized for both primary and secondary sarcopenia treatment and can be administered orally, parenterally, or enterally. These supplements are distributed through various channels including hospital pharmacies, retail pharmacies, and online pharmacies.
The sarcopenia treatment market research report is one of a series of new reports that provides sarcopenia treatment market statistics, including sarcopenia treatment industry global market size, regional shares, competitors with a sarcopenia treatment market share, detailed sarcopenia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the sarcopenia treatment industry. This sarcopenia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The sarcopenia treatment market consists of revenues earned by entities by providing nutritional therapy, combination therapy, and muscle strength. The market value includes the value of related goods sold by the service provider or included within the service offering. The sarcopenia market also includes sales of muscle stimulators, orthopedic braces and supports, joint replacement implants, anabolic agents, and more. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Sarcopenia Treatment Market Characteristics3. Sarcopenia Treatment Market Trends And Strategies32. Global Sarcopenia Treatment Market Competitive Benchmarking33. Global Sarcopenia Treatment Market Competitive Dashboard34. Key Mergers And Acquisitions In The Sarcopenia Treatment Market
4. Sarcopenia Treatment Market - Macro Economic Scenario
5. Global Sarcopenia Treatment Market Size and Growth
6. Sarcopenia Treatment Market Segmentation
7. Sarcopenia Treatment Market Regional And Country Analysis
8. Asia-Pacific Sarcopenia Treatment Market
9. China Sarcopenia Treatment Market
10. India Sarcopenia Treatment Market
11. Japan Sarcopenia Treatment Market
12. Australia Sarcopenia Treatment Market
13. Indonesia Sarcopenia Treatment Market
14. South Korea Sarcopenia Treatment Market
15. Western Europe Sarcopenia Treatment Market
16. UK Sarcopenia Treatment Market
17. Germany Sarcopenia Treatment Market
18. France Sarcopenia Treatment Market
19. Italy Sarcopenia Treatment Market
20. Spain Sarcopenia Treatment Market
21. Eastern Europe Sarcopenia Treatment Market
22. Russia Sarcopenia Treatment Market
23. North America Sarcopenia Treatment Market
24. USA Sarcopenia Treatment Market
25. Canada Sarcopenia Treatment Market
26. South America Sarcopenia Treatment Market
27. Brazil Sarcopenia Treatment Market
28. Middle East Sarcopenia Treatment Market
29. Africa Sarcopenia Treatment Market
30. Sarcopenia Treatment Market Competitive Landscape And Company Profiles
31. Sarcopenia Treatment Market Other Major And Innovative Companies
35. Sarcopenia Treatment Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Sarcopenia Treatment Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on sarcopenia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for sarcopenia treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sarcopenia treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Treatment Type: Protein Supplements; Vitamin B12 Supplements; Vitamin D And Calcium Supplements; Other Treatment Types.2) By Type: Primary Sarcopenia; Secondary Sarcopenia
3) By Route Of Administration: Oral; Parenteral; Enteral
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels.
Key Companies Mentioned: Pfizer Inc.; F-Hoffmann La-Roche; Merck Sharp & Dohme Corp. (Merck & Co.); AbbVie Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc.
- F-Hoffmann La-Roche
- Merck Sharp & Dohme Corp. (Merck & Co.)
- AbbVie Inc.
- Bayer AG
- Novartis AG
- Sanofi S.A.
- Abbott Laboratories Inc.
- GlaxoSmithKline plc
- Eli Lilly and Company
- BASF SE
- Nestle Health Science
- Haleon Group of Companies
- Regeneron Pharmaceuticals Inc.
- DSM
- American Way (Amway) Corporation
- Perrigo Company PLC
- Intas Pharmaceuticals Ltd
- Zydus Lifesciences
- Fermenta Biotech Limited
- Metagenics LLC
- Ion Labs Inc.
- Makers Nutrition LLC
- NutraScience Labs
- AstaReal AB
- NutraPak USA
- BioThrive Sciences
- Wellona Pharma
- Healing Pharma India Pvt. Ltd.
- Nutrafill
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | April 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 3.52 Billion |
| Forecasted Market Value ( USD | $ 4.44 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Global |
